2012-04-11T13:37:39-05:00 2011-05-31 KPMG LLP 60 South Street Boston MA 02111 990 2010-06-01 010211513 THE JACKSON LABORATORY JACK 2072886000 600 MAIN STREET BAR HARBOR ME 04609 LINDA JENSEN 2012-04-09 6179881000 2010 2016-02-24 21:20:13Z LINDA A JENSEN 600 MAIN STREET BAR HARBOR ME 04609 286215735 false X WWW.JAX.ORG X 1929 ME WE DISCOVER THE GENETIC BASIS FOR PREVENTING, TREATING AND CURING HUMAN DISEASE, AND WE ENABLE RESEARCH AND EDUCATION FOR THE GLOBAL BIOMEDICAL COMMUNITY. 21 21 1516 241 48973 44551 69040663 73823292 127618036 145476881 3220771 11701702 402551 512770 200282021 231514645 0 0 0 0 96734994 101918122 0 0 1893512 73772367 80264210 170507361 182182332 29774660 49332313 378980549 429077589 122889346 123384653 256091203 305692936 X WE DISCOVER THE GENETIC BASIS FOR PREVENTING, TREATING AND CURING HUMAN DISEASE, AND WE ENABLE RESEARCH AND EDUCATION FOR THE GLOBAL BIOMEDICAL COMMUNITY. false false 541710 82535399 144421450 DEVELOP AND PROVIDE GENETIC RESOURCES - PLEASE SEE SCHEDULE O FOR DETAIL. 541710 70960707 396144 BIOMEDICAL RESEARCH - PLEASE SEE SCHEDULE O FOR DETAIL. 541710 2376132 659287 EDUCATION AND TRAINING - PLEASE SEE SCHEDULE O FOR DETAIL. 155872238 true true false true false false false false true true true false false true true true false false true true false false false true false false false false true true true false false false false false false true true false true false false false false false false false false false true 193 0 true 1516 true true true true CJ BD VI false false false true true false false false false X 21 21 true false false false false false false true true false false true true true true true true true true false CA CT FL ME MA NY PA X X X LINDA A JENSEN 2072886108 600 MAIN STREET BAR HARBOR ME 04609 DAVID BALTIMORE PHD 1.0 X 0 0 0 ROBERT C BECK 1.0 X 0 0 0 DAVID R CABOT 1.0 X 0 0 0 KATHLEEN A CORBET 1.0 X 0 0 0 LOUIS J D'AMBROSIO 1.0 X 0 0 0 ROSS E DWORMAN 1.0 X 0 0 0 DAVID D ELLIMAN 1.0 X 0 0 0 ANTHONY B EVNIN PHD 1.0 X 0 0 0 JAMES J GALLOGLY 1.0 X 0 0 0 RICHARD S GURIN 1.0 X 0 0 0 WILLIAM S HARWOOD ESQ 1.0 X 0 0 0 LEO A HOLT 1.0 X 0 0 0 WESLIE R JANEWAY 1.0 X 0 0 0 RICHARD S LANNAMANN 1.0 X 0 0 0 SAM R LITTLE 1.0 X 0 0 0 TERRY R MAGNUSON PHD 1.0 X 0 0 0 TOM P MANIATIS PHD 1.0 X 0 0 0 SHIRLEY M TILGHMAN PHD 1.0 X 0 0 0 DAVID VALLE PHD 1.0 X 0 0 0 TOM S VOLPE 1.0 X 0 0 0 BRIAN WRUBLE 1.0 X 0 0 0 RICHARD P WOYCHIK PHD 40.0 X X 434322 0 107413 PETER GERRITY 1.0 X X 0 0 0 EDWARD L SAMEK 1.0 X X 0 0 0 CHARLES E HEWETT PHD 40.0 X 465611 0 134383 MICHAEL HYDE 40.0 X 292048 0 56986 LINDA JENSEN 40.0 X 289482 0 43965 JANA ROBINSON 40.0 X 46472 0 23910 RONALD SUCY 40.0 X 120724 0 19882 JOSEPH VETELINO 40.0 X 96454 0 28982 AUROBINDO NAIR PHD 40.0 X 295306 0 43944 KATHY L VANDEGRIFT 40.0 X 272527 0 40206 ROBERT BRAUN PHD 40.0 X 306413 0 25868 LEAH RAE DONAHUE PHD 40.0 X 197747 0 33066 MICHAEL WATERS 40.0 X 215520 0 41058 SUSAN D AIRHART 40.0 X 218609 0 29084 GARY A CHURCHILL PHD 40.0 X 208709 0 40686 JANAN T EPPIG PHD 40.0 X 225504 0 30408 KENNETH PAIGEN PHD 40.0 X 211804 0 0 3897252 0 699841 106 false true false COLUMBUS IT PARTNERS 750 WASHINGTON BOULEVARD 5TH FLOOR STAMFORD CT 06901 IT CONSULTING 953960 VELOCITY TECHNOLOGY SOLUTIONS 850 THIRD AVENUE NEW YORK NY 10022 IT CONSULTING 428635 HOGAN LOVELLS US LLP 111 BRICKELL AVENUE MIAMI FL 33131 LEGAL 259010 KPMG LLP 60 SOUTH STREET BOSTON MA 02111 AUDITING 299930 RMW ARCHITECTS 1718 3RD STREET SACRAMENTO CA 95811 ARCHITECTURAL 316847 13 111727 62301921 11409644 1860472 73823292 GENETIC RESOURCES 900099 144421450 144421450 TRAINING & EDUCATION 900099 659287 659287 RESEARCH 900099 396144 396144 145476881 2438188 2389215 48973 0 564979 564979 0 0 0 0 0 63841000 1886 54515340 64032 9325660 -62146 9263514 10749 111727 121718 -110969 -110969 0 0 0 Other revenue 58760 58760 58760 231514645 147924856 48973 454010 0 0 0 0 3375714 394166 2981548 0 72738902 61814706 9823522 1100674 5624204 5073249 460080 90875 14765798 13198497 1335640 231661 5413504 4599267 732342 81895 0 1357000 27604 1329396 183156 183156 66801 66801 0 200000 200000 3407611 1998965 1397937 10709 424033 323004 97843 3186 1720694 1259253 438606 22835 2670229 2318557 335597 16075 0 11907011 10703492 1164372 39147 3429977 2699605 659960 70412 0 738973 495500 231824 11649 3519314 3487934 29891 1489 0 17628798 15307067 2210521 111210 1194779 1050381 137798 6600 OTHER SERVICES 992890 915836 73297 3757 STIPENDS 622018 622018 SUPPLIES 24826714 24282648 456234 87832 EQUIPMENT RENTAL 159712 110584 46792 2336 OTHER EXPENSES 5214500 5189905 23425 1170 182182332 155872238 24416582 1893512 25000 25000 74526436 99417194 7921306 8250873 14042269 16116963 1633795 1676820 1185179 1433830 382858695 173684558 201644751 209174137 32337691 63131936 39066685 24320916 6597437 5529920 378980549 429077589 23176599 23309140 4507568 5450846 81564779 79765719 13640400 14858948 122889346 123384653 X 220315670 262173427 27543396 35201723 8232137 8317786 256091203 305692936 378980549 429077589 X 49332313 269420 X false true true X true true X false false false 69277727 66103830 66396577 69040663 73823292 344642089 69277727 66103830 66396577 69040663 73823292 344642089 344642089 3880882 4569075 4253688 3370975 2954194 19028814 97530 19815 0 21308 48973 187626 363858529 454422499 0.94719 0.94651 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 66801 false 66801 false LOBBYING ACTIVITY BY NON-ELECTING 501(C)(3) ORGANIZATION PART II-B, LINE 1G ADVOCACY ACTIVITIES IN WASHINGTON, D.C., MAINE, AND FLORIDA ARE UNDERTAKEN BY THE JACKSON LABORATORY. MAINE ACTIVITIES ARE UNDERTAKEN BY THE DIRECTOR, OFFICE OF GOVERNMENTAL RELATIONS AT THE JACKSON LABORATORY, FLORIDA ACTIVITIES ARE UNDERTAKEN BY THE DIRECTOR OF ADVANCEMENT, CHIEF OPERATING OFFICER, AND THE CHIEF EXECUTIVE OFFICER. THE LABORATORY ENGAGES A CONSULTANT IN WASHINGTON, D.C. WHO WORKS AT THE FEDERAL LEVEL ON BEHALF OF THE JACKSON LABORATORY. THE TOTAL LOBBYING EXPENSE FOR THE YEAR ENDED MAY 31, 2011 WAS $66,801, $55,420 WAS PAID TO LOBBYING FIRMS AND GROUPS. IN ADDITION, $11,381 WAS AN ALLOCATION OF EMPLOYEE COMPENSATION FOR LOBBYING ACTIVITIES. 74765000 2345649 10790669 448468 87452850 58922000 6051000 10277000 485000 74765000 80042000 76000 -20682000 514000 58922000 0.90000 0.10000 0.00000 false false 5451862 5451862 284702555 108658590 176043965 0 79667303 65025968 14641335 13036975 0 13036975 209174137 US EQUITY 8146469 F INTERNATIONAL EQUITY 8132896 F ALTERNATIVE 8041551 F 24320916 0 RETIREMENT PLANS OBLIGATION 9012845 INTEREST RATE SWAP 5747713 OTHER 98390 14858948 231514645 182182332 49332313 321353 -52225 269128 49601441 231706876 321353 -52225 269128 231437748 198615 -121718 76897 231514645 182105435 121718 121718 181983717 198615 198615 182182332 ENDOWMENT FUNDS PART V, LINE 4 THE INVESTMENT AND SPENDING POLICIES FOR THE ENDOWMENT ASSETS HAVE BEEN ESTABLISHED TO PROVIDE A PREDICTABLE STREAM OF FUNDING FOR THE PROGRAMS SUPPORTED BY ENDOWMENT INCOME, WHILE SEEKING TO MAINTAIN THE PURCHASING POWER OF THE ENDOWMENT ASSETS. IN ADDITION, WHEN CONSIDERING AMOUNT OF INCOME TO APPROPRIATE FROM BOARD-DESIGNATED ASSETS, THE TRUSTEES CONSIDER THE NEED TO MAINTAIN UNRESTRICTED ASSETS TO MEET LIQUIDITY COVENANTS RELATED TO OUTSTANDING BONDS. ACCORDINGLY, THE BOARD OF TRUSTEES HAS SET THE INVESTMENT ALLOCATION TO ACHIEVE A NOMINAL RATE OF RETURN THAT WILL AT LEAST COVER INFLATION AND THE SPEND RATE WITH A PRUDENT LEVEL OF RISK. THE INVESTMENT ALLOCATION FOR THE BOARD-DESIGNATED PORTION OF THE ENDOWMENT IS SET TO ACHIEVE GREATER STABILITY IN THE VALUE OF THE INVESTMENTS. THE BOARD ALLOCATED 4% OF THE THREE YEAR AVERAGE VALUE OF DONOR-DESIGNATED ENDOWMENT BALANCES TO SUPPORT THE DESIGNATED PROGRAMS. ALL EARNINGS ON DONOR ENDOWMENTS ESTABLISHED TO PROVIDE GENERAL SUPPORT FOR THE LABORATORY AS APPROVED BY THE BOARD OF TRUSTEES WERE RETAINED IN THE ENDOWMENT. THE BOARD OF TRUSTEES WISHES TO INCREASE THE AMOUNT OF ENDOWMENT SUPPORT AVAILABLE IN THE FUTURE. LIABILITY FOR UNCERTAIN TAX POSITIONS UNDER FIN 48 (ASC 740) PART XI, LINE 2 THE LABORATORY IS A NOT-FOR-PROFIT ORGANIZATION AS DESCRIBED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (THE CODE), AS AMENDED AND IS GENERALLY EXEMPT FROM INCOME TAXES PURSUANT TO THE CODE. THE LABORATORY ASSESSES WHETHER THERE ARE UNCERTAIN TAX POSITIONS AND DETERMINED THAT THERE WERE NO UNCERTAIN TAX POSITIONS THAT WOULD HAVE A MATERIAL EFFECT ON THE FINANCIAL STATEMENTS. OTHER CHANGES IN NET ASSETS PART XI, LINE 8 UNREALIZED LOSS ON INTEREST RATE SWAPS (335,174) CHANGES IN ACTUARIAL ASSUMPTIONS 282,948 ROUNDING 1 TOTAL (52,225) OTHER REVENUE INCLUDED IN FINANCIAL STATEMENTS BUT NOT ON RETURN PART XII, LINE 2D UNREALIZED LOSS ON INTEREST RATE SWAPS (335,174) CHANGES IN ACTUARIAL ASSUMPTIONS 282,948 ROUNDING 1 TOTAL (52,225) OTHER REVENUE ON RETURN NOT IN FINANCIAL STATEMENTS PART XII, LINE 4B RECLASS OF FUNDRAISING EXPENSE (121,719) OTHER EXPENSES INCLUDED IN FINANCIAL STATEMENTS NOT ON RETURN PART XIII, LINE 2D RECLASS OF FUNDRAISING EXPENSE 121,719 Europe (Including Iceland and Greenland) 0 2 Program Services RESEARCH 141349 South Asia 0 0 Program Services TRAINING 13121 Central America and the Caribbean 0 0 Investments 11792168 0 2 0 2 11946638 11946638 false false false true true false Awards Dinner 73079 62874 10205 90899 Discovery Lunch 34683 34139 544 16105 1 14714 14714 14714 122476 111727 10749 121718 121718 -110969 X true true X X X X X false true false false false false false true false RICHARD P WOYCHIK PHD 409322 0 25000 0 0 0 86153 0 21260 0 541735 0 0 0 CHARLES E HEWETT PHD 435611 0 30000 0 0 0 115000 0 19383 0 599994 0 0 0 MICHAEL HYDE 267048 0 25000 0 0 0 37500 0 19486 0 349034 0 0 0 LINDA JENSEN 254482 0 35000 0 0 0 24500 0 19465 0 333447 0 0 0 MICHAEL WATERS 178104 0 37416 0 0 0 21733 0 19325 0 256578 0 0 0 SUSAN D AIRHART 175229 0 43379 0 0 0 21945 0 7139 0 247693 0 0 0 GARY A CHURCHILL PHD 208709 0 0 0 0 0 21302 0 19384 0 249395 0 0 0 JANAN T EPPIG PHD 225504 0 0 0 0 0 22730 0 7678 0 255912 0 0 0 KENNETH PAIGEN PHD 211804 0 0 0 0 0 0 0 0 0 211804 0 0 0 AUROBINDO NAIR PHD 240181 0 55125 0 0 0 24500 0 19444 0 339250 0 0 0 KATHY L VANDEGRIFT 222746 0 49781 0 0 0 24500 0 15706 0 312733 0 0 0 ROBERT BRAUN PHD 306413 0 0 0 0 0 24500 0 1368 0 332281 0 0 0 LEAH RAE DONAHUE PHD 172747 0 25000 0 0 0 18895 0 14171 0 230813 0 0 0 BENEFITS PART I, LINE 1A TAX INDEMNIFICATION AND GROSS-UP PAYMENTS: THE JACKSON LABORATORY GROSSES UP THE AMOUNT ADDED TO WAGES FOR IMPUTED INSURANCE PREMIUMS FOR THE SENIOR MANAGEMENT GROUP TO COVER TAXES. THE LABORATORY ALSO GROSSES UP WAGES TO COVER THE TAX IMPACT OF GIFT CARDS AND OTHER AWARDS OR PRIZES TO EMPLOYEES SO THAT THE RECIPIENTS RECEIVE THE FULL VALUE OF THE GIFT OR AWARD. SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN PART I, LINE 4B THE LABORATORY MAINTAINS DEFERRED COMPENSATION PLANS UNDER SECTIONS 457(B) AND 457(F). THE 457(B) PLAN ALLOWS HIGHLY COMPENSATED EMPLOYEES TO DEFER AN ADDITIONAL $16,500 OF THEIR SALARY EACH CALENDAR YEAR. THE PRESIDENT AND EXECUTIVE VICE PRESIDENT/COO PARTICIPATE IN A NON-QUALIFIED SUPPLEMENTAL RETIREMENT PLAN THAT PROVIDES FOR A PORTION OF THEIR COMPENSATION TO BE DEFERRED UNDER A SECTION 457 (F) PLAN. THE AMOUNT TAXABLE TO THEM UNDER THE PLAN DURING THE YEAR IS $0. NON-FIXED PAYMENTS PART I, LINE 7 THE TOTAL COMPENSATION PACKAGE OF CERTAIN OFFICERS AND KEY EMPLOYEES INCLUDES VARIABLE COMPENSATION AWARDED BASED ON PERFORMANCE. ABAG FINANCE AUTHORITY FOR NONPROFIT CORPORATIONS 943130123 00037CLX6 2007-09-12 35075000 FINANCE CONSTRUCTION & REFUND false false false 35075000 1004292 456682 31597588 2016438 2009 true false true true false false true true true 0.00290 0.00000 0.00290 true false false false false true true TAX-EXEMPT BOND PART I COLUMN (F) DESCRIPTION OF PURPOSE: FINANCE CONSTRUCTION AND REFUND $2 MILLION IN OUTSTANDING ABAG 2002 REVENUE BOND. OTHER SPENT PROCEEDS PART II, LINE 11 $2,016,438 SHALL BE USED TO REIMBURSE THE ISSUER OF A LETTER OF CREDIT WITH RESPECT TO THE 2002 BONDS FOR AN ADVANCE TO PAY THE COSTS OF REDEEMING THE REFUNDED BONDS AND SHALL BE ALLOCATED TO REDEMPTION OF THE REFUNDED BONDS FOR PURPOSES OF THIS TAX CERTIFICATE. GROSS PROCEEDS INVESTED BEYOND AN AVILABLE TEMPORARY PERIOD PART IV, LINE 5 $3,544 WAS HELD BEYOND THE APPLICABLE TEMPORARY PERIOD, EARNING DE MINIMIS INTEREST. JAX PARTNERS II SEE PART V 273454 CAPITAL CONTRIBUTION false MADELEINE BRAUN KEY EMPLOYEE-ROBERT BRAUN 168616 EMPLOYMENT - FAMILY MEMBER false BUSINESS TRANSACTIONS WITH INTERESTED PERSON PART IV JAX PARTNERS I AND II ARE ENTITIES IN WHICH THE JACKSON LABORATORY AND TRUSTEE, ROBERT C. BECK, ARE SERVING AS PARTNERS IN A PASS THROUGH INVESTMENT VEHICLE WITH A DIRECT OWNERSHIP INTEREST IN A PRIVATE EQUITY FUND. X 44 338815 FMV X 1 1500000 FMV X IN-KIND CONTRIBUTIONS 6 21657 FMV 0 false true false ORGANIZATION'S MISSION FORM 990, PART III, LINE 1 THE MISSION OF THE LABORATORY IS THREEFOLD: 1.) CONDUCTING BASIC BIOMEDICAL RESEARCH; 2.) TRAINING AND EDUCATING SCIENTISTS WORLDWIDE; 3.) PROVIDING GENETIC RESOURCES TO THE GLOBAL SCIENTIFIC COMMUNITY. THE PURPOSE OF THE LABORATORY IS TO INCREASE THE KNOWLEDGE OF DEVELOPMENT, GROWTH, REPRODUCTION, PHYSIOLOGICAL, AND INBORN ALIMENTS THROUGH RESEARCH WITH GENETICALLY DEFINED EXPERIMENTAL ANIMALS. PROGRAM SERVICES FORM 990, PART III, LINE 4A-4C 4A. GENETIC RESOURCES THE JACKSON LABORATORY GENERATES AND MAINTAINS OPEN-SOURCE DATABASES THAT ARE AVAILABLE TO THE WORLDWIDE RESEARCH COMMUNITY, DRIVING DISCOVERY IN CANCER, DIABETES, OSTEOPOROSIS, ALZHEIMER'S DISEASE AND MANY OTHER AREAS CRITICAL TO HUMAN HEALTH. THROUGHOUT FISCAL YEAR 2011, THESE DATABASES EXPERIENCED CLOSE TO 9 MILLION "HITS" PER WEEK. THE LABORATORY'S MOUSE REPOSITORY OFFERED A PORTFOLIO OF OVER 2,500 TARGETED AND 1,200 TRANSGENIC MUTANT MOUSE LINES. THESE INCLUDED A WIDE SELECTION OF STRAINS GENETICALLY ENGINEERED AS MOUSE MODELS OF HUMAN DISEASES, AMONG THEM CANCER, HEART DISEASE, ALZHEIMER'S DISEASE, ALS, DIABETES, PARKINSON'S DISEASE, SPINAL MUSCULAR ATROPHY, HUNTINGTON'S DISEASE AND VARIOUS AUTOIMMUNE DISEASES. TO INCREASE THE NUMBER OF NEW CANCER DRUGS THAT ARE BOTH SAFE AND EFFECTIVE IN PATIENTS, THE JACKSON LABORATORY IS PARTNERING WITH THE UC DAVIS CANCER CENTER AND THE NATIONAL CANCER INSTITUTE'S (NCI) CENTER FOR ADVANCED PRECLINICAL RESEARCH (CAPR), ALL UNDER THE UMBRELLA OF NCI'S ADVANCED TECHNOLOGY PARTNERSHIPS INITIATIVE (ATPI). UNDER THE PARTNERSHIP, THE JACKSON LABORATORY SUCCESSFULLY DEVELOPED A GENETICALLY ENGINEERED MOUSE MODEL CAPABLE OF ACCEPTING THE ENGRAFTMENT OF HUMAN TISSUE. 4B. RESEARCH PROFESSOR JOHN EPPIG, A PIONEER IN DEVELOPMENTAL AND REPRODUCTIVE BIOLOGY, WAS ELECTED TO THE NATIONAL ACADEMY OF SCIENCES, ONE OF THE TOP HONORS IN AMERICAN SCIENCE. A JACKSON LABORATORY RESEARCH TEAM LED BY PROFESSOR SIMON JOHN AND COLLABORATORS REPORTED THEY HAVE DESIGNED AN ANALYSIS TECHNIQUE THAT DETECTS EARLY STAGES OF GLAUCOMA IN MICE, AND HAVE SUCCESSFULLY BLOCKED THE DISEASE BY TARGETING SOME OF THE MOLECULAR EVENTS IN THOSE EARLY STAGES. DR. JOHN'S LABORATORY ALSO REPORTED THEIR FINDING THAT RNA GRANULES-KEY PLAYERS IN MESSENGER RNA (MRNA) PROCESSING-CAN AFFECT EYE DEVELOPMENT, LEADING TO JUVENILE CATARACTS AND GLAUCOMA IN HUMANS AND MICE, AND THEIR DISCOVERY OF A GENE IMPLICATED IN AN ACUTE AND SEVERE FORM OF GLAUCOMA KNOWN AS ANGLE-CLOSURE GLAUCOMA. JACKSON LABORATORY PROFESSOR GARY CHURCHILL AND COLLABORATORS AT THE UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL, CREATED A GENOME-WIDE, HIGH-RESOLUTION MAP OF MOST OF THE INBRED MOUSE STRAINS USED TODAY. THEIR CONCLUSION, PUBLISHED IN NATURE GENETICS: MOST OF THE MICE IN USE TODAY REPRESENT ONLY LIMITED GENETIC DIVERSITY, WHICH COULD BE SIGNIFICANTLY EXPANDED WITH THE ADDITION OF MORE WILD MOUSE POPULATIONS. RESEARCHERS AT THE JACKSON LABORATORY LED BY ASSISTANT PROFESSOR ZHONG-WEI ZHANG HAVE DISCOVERED A FACTOR IN SYNAPSE BUILDING, ALSO SHOWING THAT THE INTRICATE PROCESSES OF SYNAPSE BUILDING AND PRUNING OCCUR INDEPENDENT OF EACH OTHER. A RESEARCH TEAM INCLUDING JACKSON LABORATORY PROFESSOR DERRY ROOPENIAN SHOWED THAT BY PAIRING WITH A SPECIAL RECEPTOR, KNOWN AS FCRN, ANTIBODIES CAN ENTER CELLS THAT HAVE BEEN INVADED BY INFLUENZA VIRUS AND SHUT DOWN THEIR REPLICATION MACHINERY. A BETTER UNDERSTANDING OF HOW-AND WHERE-THE ANTIBODIES FIGHT VIRUSES IS IMPORTANT FOR DESIGNING NEW AND MORE EFFECTIVE VACCINES AND ANTIBODY-BASED THERAPIES. JACKSON LABORATORY RESEARCH SCIENTIST CAT LUTZ, PH.D., AND COLLABORATORS AT COLUMBIA UNIVERSITY AND OTHER LABORATORIES, DEMONSTRATED A NEW APPROACH TO TREATING THE DEVASTATING NEUROMUSCULAR DISEASE KNOWN AS SPINAL MUSCULAR ATROPHY (SMA). WORKING WITH A NEW MOUSE MODEL OF SMA, THE RESEARCHERS REDUCED THE SYMPTOMS OF THE DISEASE BY RESTORING LEVELS OF A PROTEIN CALLED SMN. 4C. TRAINING THE JACKSON LABORATORY PROVIDED 29 COURSES, CONFERENCES, SEMINARS AND WORKSHOP EVENTS. THESE UNIQUE EDUCATIONAL OPPORTUNITIES ATTRACTED 691 PARTICIPANTS FROM THROUGHOUT THE NATIONAL AND INTERNATIONAL RESEARCH COMMUNITY, AFFORDING THEM WITH OPPORTUNITIES TO TRADE INSIGHTS WITH 404 FACULTY MEMBERS. THE JACKSON LABORATORY HAS OFFERED SCHOOL-YEAR INTERNSHIPS TO HIGH SCHOOL STUDENTS FROM REGIONAL HIGH SCHOOLS SINCE 1993. THIS PROGRAM IN FISCAL YEAR 2011 ATTRACTED EIGHT STUDENTS. THE LABORATORY'S COLLEGE INTERNSHIP PROGRAM ALSO PROVIDED ON-CAMPUS, SEMESTER-LONG INDEPENDENT RESEARCH PROJECTS TO FOUR STUDENTS. YET ANOTHER HAND-ON PROGRAM FOR SCIENCE TEACHERS ATTRACTED THREE PARTICIPANTS. THE JACKSON LABORATORY'S HISTORIC SUMMER STUDENT PROGRAM HAD 38 TALENTED PARTICIPANTS. THE NATIONALLY RENOWNED PROGRAM PROVIDES HIGH SCHOOL AND COLLEGE STUDENTS WITH AN OPPORTUNITY TO CONDUCT INDEPENDENT RESEARCH UNDER THE GUIDANCE OF STAFF SCIENTISTS. MORE THAN 2,200 STUDENTS, INCLUDING THREE NOBEL LAUREATES, HAVE PARTICIPATED IN THE PROGRAM. MOST ALUMNI GO ON TO CAREERS IN MEDICINE OR RESEARCH. COMMITMENT TO EDUCATIONAL OUTREACH EXTENDS INTO REGIONAL ELEMENTARY SCHOOLS. FISCAL YEAR 2011 SAW THE CONTINUATION OF THE POPULAR, LITERALLY HANDS-ON -BACTERIOLOGY COURSE IN WHICH SECOND-GRADERS LEARN ABOUT THE COMMON GERMS THAT LIVE ON THE PALMS OF THEIR HANDS. THESE COURSES ARE CONDUCTED PRIMARILY WITH THE USE OF RESEARCH STAFF VOLUNTEERS, INCLUDING FACULTY MEMBERS, POSTDOCTORAL STUDENTS AND RESEARCH ASSISTANTS. FORM 990 REVIEW PROCESS PART VI, SECTION B, QUESTION 11A THE AUDIT COMMITTEE OF THE JACKSON LABORATORY'S BOARD OF TRUSTEES REVIEWS A DRAFT COPY OF THE IRS FORM 990 BEFORE IT IS PROVIDED TO THE BOARD OF TRUSTEES. AFTER REVIEW, THE IRS FORM 990 IS FINALIZED AND FILED. CONFLICT OF INTEREST POLICY PART VI, SECTION B, QUESTION 12C THE JACKSON LABORATORY ANNUALLY PROVIDES ALL OFFICERS, BOARD MEMBERS AND KEY EMPLOYEES WITH A CONFLICT OF INTEREST, CODE OF ETHICS AND DISCLOSURE QUESTIONNAIRE ACCOMPANIED WITH COPIES OF ALL RELATED POLICIES. THE DISCLOSURE AND COMPLIANCE ATTESTATIONS ARE RETURNED TO TRUSTEE RELATIONS, WHERE THEY ARE RECORDED AND TALLIED FOR COMPLETENESS. ANY ISSUES NOTED ARE REFERRED TO THE AUDIT COMMITTEE. THE CHIEF FINANCIAL OFFICER ALSO REVIEWS THE RESPONSES TO IDENTIFY ANY ITEMS THAT REQUIRE DISCLOSURE. COMPENSATION POLICY PART VI, SECTION B, QUESTION 15B THE COMPENSATION AND HUMAN RESOUCES COMMMITTEE OF THE BOARD OF TRUSTEES SETS COMPENSATION AND BENEFITS FOR THE CHIEF EXECUTIVE OFFICER, EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER, THE ASSOCIATE DIRECTOR AND CHAIR OF RESEARCH, THE VICE PRESIDENT FOR ADVANCEMENT AND EXTERNAL RELATIONS, THE CHIEF FINANCIAL OFFICER AND EQUIVALENT POSITIONS AS WELL AS ANY OTHER EMPLOYEES OF THE LABORATORY WHO WOULD BE CONSIDERED 'INSIDERS' OR 'DISQUALIFIED PERSONS' WITHIN THE MEANING OF THE INTERMEDIATE SANCTIONS RULES UNDER THE INTERNAL REVENUE CODE. MEMBERS OF THE COMMITTEEE ARE INDEPENDENT TRUSTEES SELECTED BY THE CHAIR OF THE BOARD OF TRUSTEES. THE COMMITTEE IS GUIDED BY MARKET DATA OF COMPENSATION PACKAGES FOR SIMILAR POSITIONS IN COMPARABLE ORGANIZATIONS. MARKET DATA IS PREPARED FOR THE COMMITTEE BY AN EXTERNAL EXECUTIVE COMPENSATION FIRM WHICH CONSIDERS COMPENSATION INFORMATION REPORTED IN FORM 990'S OF COMPARABLE ORGANIZATIONS AND THE RESULTS OF RECOGNIZED COMPENSATION SURVEYS. THE SENIOR DIRECTOR OF HUMAN RESOURCES IS AVAILABLE TO THE COMMITTEE TO PROVIDE ANY OTHER DATA NEEDED. THE CEO MEETS WITH THE COMMITTEE AT LEAST ANNUALLY TO PROVIDE THE COMMITTEE MEMBERS WITH ANNUAL PERFORMANCE REVIEWS OF HIS REPORTS. THE COMMITTEE'S REVIEW PROCESS AND RESULTS ARE DOCUMENTED IN MINUTES OF THE MEETINGS. PUBLIC DISCLOSURE PART VI, SECTION C, QUESTION 19 THE ORGANIZATION'S FORM 990 IS AVAILABLE ON WWW.GUIDESTAR.ORG AND ON THE ORGANIZATION'S PUBLIC WEBSITE JAX.ORG. OTHER CHANGES IN NET ASSETS PART XI, LINE 5 UNREALIZED GAIN 321,353 UNREALIZED LOSS ON INTEREST RATE SWAPS (335,174) CHANGES IN ACTUARIAL ASSUMPTIONS 282,948 ROUNDING 293 TOTAL 269,420